CVS Health (NYSE:CVS) Director Larry Robbins Sells 1,983,538 Shares

CVS Health Corporation (NYSE:CVS) Director Larry Robbins sold 1,983,538 shares of the firm’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the sale, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Larry Robbins also recently made the following trade(s):

• On Thursday, May 21st, Larry Robbins sold 370,462 shares of CVS Health stock. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90.
• On Wednesday, May 20th, Larry Robbins sold 1,018,000 shares of CVS Health stock. The shares were sold at an average price of $93.82, for a total value of $95,508,760.00.

CVS Health Price Performance

Shares of NYSE CVS opened at $93.35 on Friday. The stock has a market cap of $119.11 billion, a PE ratio of 41.12, a price-to-earnings-growth ratio of 0.91 and a beta of 0.60. CVS Health Corporation has a fifty-two week low of $58.50 and a fifty-two week high of $98.43. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The stock has a fifty day moving average of $80.03 and a 200-day moving average of $78.98.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.36. The company had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts anticipate that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.8%. The ex-dividend date was Thursday, April 23rd. CVS Health’s payout ratio is presently 117.18%.

Hedge Funds Weigh In On CVS Health

A number of hedge funds and other institutional investors have recently modified their holdings of CVS. National Pension Service lifted its stake in shares of CVS Health by 3.1% in the 3rd quarter. National Pension Service now owns 3,999,622 shares of the pharmacy operator’s stock valued at $301,532,000 after acquiring an additional 119,189 shares during the last quarter. Kingsview Wealth Management LLC lifted its stake in shares of CVS Health by 316.2% in the 3rd quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock valued at $7,873,000 after acquiring an additional 79,340 shares during the last quarter. AE Wealth Management LLC lifted its stake in shares of CVS Health by 6.2% in the 3rd quarter. AE Wealth Management LLC now owns 257,204 shares of the pharmacy operator’s stock valued at $19,391,000 after acquiring an additional 14,983 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of CVS Health by 11.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 225,116 shares of the pharmacy operator’s stock valued at $16,971,000 after acquiring an additional 22,653 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in shares of CVS Health by 186.6% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 396,368 shares of the pharmacy operator’s stock valued at $30,568,000 after acquiring an additional 258,050 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Glenview Capital said its CVS position has produced about an 80% total return since May 2024, signaling continued investor confidence in CVS’s long-term turnaround and helping reinforce the bullish case. Glenview Capital Issues Statement on CVS Health
• Positive Sentiment: Recent company-news items highlighting community programs, military support, and affordable senior housing may modestly support CVS’s brand and long-term ESG narrative, though they are unlikely to move the stock as much as the legal headlines. CVS Health, Diocese of Camden, and The Walters Group Unite to Bring Senior Affordable Housing to Williamstown, New Jersey
• Neutral Sentiment: Director Larry Robbins disclosed large stock sales over several days, including a roughly $187 million sale and other sizable transactions, but he still retains a large stake; the filings may be read as routine diversification rather than a full exit. SEC Form 4 filing
• Negative Sentiment: Hospitals allege CVS and its affiliates secretly captured 340B savings, which could lead to litigation costs, potential settlements, and tighter oversight of CVS’s pharmacy-benefit operations. Hospitals allege contracted CVS Health subsidiaries pocketed their 340B savings
• Negative Sentiment: Separate reports from the University of Michigan and University of Kansas hospital systems expanded the dispute and added to concerns that CVS could face multiple 340B-related lawsuits and rising legal exposure. CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment

Analyst Ratings Changes

CVS has been the subject of several recent analyst reports. Wolfe Research reduced their target price on CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a research report on Monday, March 2nd. Argus boosted their target price on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday, May 14th. Royal Bank Of Canada boosted their target price on CVS Health from $93.00 to $107.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Leerink Partners restated an “outperform” rating and set a $98.00 target price on shares of CVS Health in a research report on Thursday, March 5th. Finally, DA Davidson boosted their target price on CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.68.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.